Psoriasis Clinical Trial

Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis

Summary

The purpose of this study is to compare the efficacy and safety of deucravacitinib to placebo in participants with moderate-to-severe scalp psoriasis.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Men and women diagnosed with stable plaque psoriasis with scalp involvement for 6 months or more. Stable psoriasis is defined as no morphology changes or significant flares of disease activity in the opinion of the Investigator
Deemed by the Investigator to be a candidate for phototherapy or systemic therapy
Moderate-to-severe scalp psoriasis as defined by scalp-specific Physician's Global Assessment (ss-PGA) ≥ 3; ≥ 20% scalp surface area (SSA); Psoriasis Scalp Severity Index (PSSI) ≥ 12 at the Screening visit and Day 1
≥ 3% of Body Surface Area (BSA) involvement at the Screening visit and Day 1
Evidence of plaque psoriasis in a non-scalp area
Failed to respond to, or intolerant of ≥ 1 topical therapy for scalp psoriasis

Exclusion Criteria:

Target Disease Exceptions:

Has nonplaque psoriasis (ie, guttate, inverse, pustular, erythrodermic or drug-induced psoriasis) at Screening or Day 1 Other protocol-defined inclusion/exclusion criteria apply

Study is for people with:

Psoriasis

Phase:

Phase 4

Estimated Enrollment:

152

Study ID:

NCT05478499

Recruitment Status:

Active, not recruiting

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 29 Locations for this study

See Locations Near You

Local Institution - 0001
Hot Springs Arkansas, 71913, United States
Local Institution - 0007
Indianapolis Indiana, 46256, United States
Local Institution - 0041
Louisville Kentucky, 40217, United States
Local Institution - 0022
Rockville Maryland, 20850, United States
Local Institution - 0008
Beverly Massachusetts, 01915, United States
Local Institution - 0047
Bloomfield Hills Michigan, 48302, United States
Local Institution - 0002
Fridley Minnesota, 55432, United States
Local Institution - 0049
East Windsor New Jersey, 08520, United States
Local Institution - 0051
Kew Gardens New York, 11415, United States
Local Institution - 0003
Portland Oregon, 97201, United States
Local Institution - 0005
Pittsburgh Pennsylvania, 15213, United States
Local Institution - 0033
Houston Texas, 77004, United States
Local Institution - 0004
San Antonio Texas, 78229, United States
Local Institution - 0006
Norfolk Virginia, 23502, United States
Local Institution - 0019
Paris , 75010, France
Local Institution - 0040
Romans sur Isere Cedex , 26102, France
Local Institution - 0044
Rouen Cedex , 76031, France
Local Institution - 0038
Witten Deutschland, 58454, Germany
Local Institution - 0013
Frankfurt Hessen, 60590, Germany
Local Institution - 0048
Hamburg , 20246, Germany
Local Institution - 0012
Luebeck , 23538, Germany
Local Institution - 0011
Mahlow , 15831, Germany
Local Institution - 0026
Krakow , 30438, Poland
Local Institution - 0017
Lodz , 90-43, Poland
Local Institution - 0014
Rzeszow , 35-05, Poland
Local Institution - 0015
Wroclaw , 51-68, Poland
Local Institution - 0031
London Greater London, SE1 9, United Kingdom
Local Institution - 0045
Salford Greater Manchester, M6 8H, United Kingdom
Local Institution - 0039
Southampton Hampshire, SO16 , United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Psoriasis

Phase:

Phase 4

Estimated Enrollment:

152

Study ID:

NCT05478499

Recruitment Status:

Active, not recruiting

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.